Marksans Pharma Limited Bombay S.E.

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-12 am EDT			5-day change	1st Jan Change
189 ^INR	-1.72%		+0.59%	+17.50%

Jul. 02	Marksans Pharma Gets UK Regulator's Nod for Two Products	MT
May. 31	Transcript : Marksans Pharma Limited, Q4 2024 Earnings Call, May 31, 2024

Marksans Pharma Limited Announces Resignation of Naresh Balwant Wadhwa as Director

January 02, 2018 at 06:23 am EST

Marksans Pharma Limited announced the resignation of Mr. Naresh Balwant Wadhwa as Director of the company with effect from January 02, 2018.

Latest news about Marksans Pharma Limited

Marksans Pharma Gets UK Regulator's Nod for Two Products	Jul. 02	MT
Transcript : Marksans Pharma Limited, Q4 2024 Earnings Call, May 31, 2024	May. 31
INDIA STOCKS-Indian shares fall for fifth session on weak global cues, election uncertainties	May. 30	RE
Marksans Pharma's Consolidated Profit Declines in Fiscal Q4; Shares Fall 9%	May. 30	MT
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 30	CI
Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24	May. 30	CI
Marksans Pharma Gets Marketing Approval for Levetiracetam Relonchem in UK	May. 28	MT
Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA	Apr. 18	MT
Transcript : Marksans Pharma Limited Presents at Bharat Connect Conference - Rising Stars 2024, Mar-26-2024	Mar. 25
Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024	Feb. 14
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Transcript : Marksans Pharma Limited, Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets	Nov. 06	MT
Marksans Pharma Undergoes Successful Inspection from German Health Authorities	Nov. 01	MT
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable	23-10-12	MT
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules	23-10-03	MT
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg	23-10-03	CI
Marksans Pharma Limited Approves Payment of Dividend	23-08-28	CI
Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director	23-08-28	CI
Marksans Pharma Gets US FDA's Final Approval for Generic Cough Medicine	23-08-22	MT
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets	23-08-22	CI
Transcript : Marksans Pharma Limited, Q1 2024 Earnings Call, Aug 16, 2023	23-08-16
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23	23-08-08	CI

Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

189.2 INR

Average target price

215 INR

Spread / Average Target

+13.66%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals

Marksans Pharma Limited Bombay S.E.

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Marksans Pharma Limited Announces Resignation of Naresh Balwant Wadhwa as Director

Latest news about Marksans Pharma Limited

Chart Marksans Pharma Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals